Anova analysis to reveal drug sensitivity markers.

<p>The sensitivity of drugs for twenty-three common cancer gene mutations was analysed statistically through Anova, based on the IC₅₀ data on forty-four cell lines, and depicted in volcano plots. On the x-axis: IC₅₀ shift between wild type and mutant cell lines. On the y-axis: p-value for significance in the Anova variance test. Significance was corrected for multiple-testing and all associations above the threshold (dotted line) were colored green [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125021#pone.0125021.ref031" target="_blank">31</a>]. In panels B and C no associations are above the multiple testing threshold and therefore no dotted line is shown. Areas of circles are proportional to the number of cell lines carrying mutations. <b>A</b>: The Wnt-pathway inhibitor ICG-001 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125021#pone.0125021.ref039" target="_blank">39</a>] is relatively potent in cell lines containing <i>CTNNB1</i> or <i>MSH2</i> mutations. <b>B</b>: the EGFR inhibitor neratinib (HKI-272) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125021#pone.0125021.ref061" target="_blank">61</a>] is relatively potent in cell lines containing <i>MSH1</i>, <i>SMAD4</i> mutations, or <i>MYC</i> amplifications (blue). <b>C</b>: the Aurora inhibitor GSK-1070916 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0125021#pone.0125021.ref062" target="_blank">62</a>] is relatively potent in cell lines containing <i>MYC</i> amplifications (blue) or <i>ABL</i> translocations.